Want to see IRON full AI Analyst Report?
IRON Stock Chart & Stats
$74.12
$0.49(0.66%)
At close: 4:00 PM EDT
$74.12
$0.49(0.66%)
Day’s Range― - ―
52-Week Range$40.00 - $99.50
Previous Close$74.61
Volume355.43K
Average Volume (3M)666.06K
Market Cap
$3.03B
Enterprise Value$2.17K
Total Cash (Recent Filing)$717.75M
Total Debt (Recent Filing)$1.52M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 05, 2026EPS Estimate
-1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.60
Shares Outstanding38,199,090
10 Day Avg. Volume352,719
30 Day Avg. Volume666,056
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$98.86Price Target Upside33.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-6.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseDisc Medicine’s very low debt relative to substantial shareholders’ equity provides durable financial flexibility to fund lengthy clinical programs and negotiate partnerships. A strong equity cushion reduces immediate solvency risk and supports strategic optionality over the next 6–24 months as trials progress.
Expanded, Extended Debt FacilityThe Hercules loan amendment structurally extends access to committed capital and delays covenant testing, materially stretching runway. This shift reduces near-term liquidity pressure and increases optionality to complete pivotal work or secure partnerships without precipitous financing events.
Advancing Clinical Pipeline And EnrollmentProgress across multiple programs—Phase 3 readout, early access program, and a fully enrolled Phase 2—represents durable de-risking milestones. Successful readouts or positive Phase 2 data can convert research-stage assets into pivotal candidates and materially change the company’s long-term commercial trajectory.
Bears Say
Pre-revenue With Accelerating LossesBeing pre-revenue, the company lacks operating income to offset rising R&D and G&A spend. Rapidly widening net losses mean returns are negative and operating leverage is absent; absent clear commercial milestones, losses can continue to erode capital and increase financing frequency over the medium term.
Deep, Worsening Cash BurnSustained, large negative operating and free cash flows indicate high runway consumption from clinical programs. This persistent cash burn necessitates repeated external funding and constrains long-term planning, making continued R&D progress contingent on securing new capital or partnerships.
Reliance On External Financing And Dilution RiskWithout product revenue, Disc Medicine structurally depends on equity, debt draws, or collaborations to fund operations. Even with expanded facilities, repeated capital raises or dilutive financings remain likely if clinical programs require more cash, posing long-term dilution and governance trade-offs for shareholders.
Disc Medicine News
IRON FAQ
What was Disc Medicine, Inc.’s price range in the past 12 months?
Disc Medicine, Inc. lowest stock price was $40.00 and its highest was $99.50 in the past 12 months.
What is Disc Medicine, Inc.’s market cap?
Disc Medicine, Inc.’s market cap is $3.03B.
When is Disc Medicine, Inc.’s upcoming earnings report date?
Disc Medicine, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 95 days.
How were Disc Medicine, Inc.’s earnings last quarter?
Disc Medicine, Inc. released its earnings results on Jul 30, 2026. The company reported -$1.54 earnings per share for the quarter, beating the consensus estimate of -$1.713 by $0.173.
Is Disc Medicine, Inc. overvalued?
According to Wall Street analysts Disc Medicine, Inc.’s price is currently Undervalued.
Does Disc Medicine, Inc. pay dividends?
Disc Medicine, Inc. does not currently pay dividends.
What is Disc Medicine, Inc.’s EPS estimate?
Disc Medicine, Inc.’s EPS estimate is -1.67.
How many shares outstanding does Disc Medicine, Inc. have?
Disc Medicine, Inc. has 38,199,090 shares outstanding.
What happened to Disc Medicine, Inc.’s price movement after its last earnings report?
Disc Medicine, Inc. reported an EPS of -$1.54 in its last earnings report, beating expectations of -$1.713. Following the earnings report the stock price went up 7.52%.
Which hedge fund is a major shareholder of Disc Medicine, Inc.?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.86 (33.37% Upside)
$98.86 (33.37% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 246.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.53%
Trailing 12-Months
Company Description
Disc Medicine, Inc.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
IRON Stock 12 Month Forecast
Average Price Target
$98.86
▲(33.37% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
8.86% Insiders
27.28% Mutual Funds
1.49% Other Institutional Investors
49.74% Public Companies and
Individual Investors